Search results for "Pamidronate"

showing 4 items of 4 documents

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review

2015

Introduction: Orthodontic anchorage is one of the most challenging aspects of Orthodontics. Preventing undesired movement of teeth could result in safer and less complicated orthodontic treatment. Recently, several reviews have been published about the effects of different molecules on bone physiology and the clinical side effects in Orthodontics. However, the effects of local application of these substances on the rate of orthodontic tooth movement have not been assessed.Objectives: The aim of this research was to analyze the scientific evidence published in the literature about the effects of different molecules on orthodontic anchorage.Methods: The literature was systematically reviewed …

Bone remodeling periodBisfosfonatosTooth Movement TechniquesMovimentação dentáriaPharmacological managementAnti-Inflammatory AgentsOsteoclastsPamidronateDentistryZoledronic AcidAntioxidantsLactonesMiceStilbenesOrthodontic Anchorage ProceduresMedicineAgentes anti-inflamatóriosSulfonesAnti-inflammatory agentsOrthodonticsDiphosphonatesOsteoprotegerinaImidazolesOrthodontic anchorage proceduresArticlesBisphosphonatesProcedimentos de ancoragem ortodônticaTooth movementInclusion and exclusion criteriaBone RemodelingTooth MobilityOral SurgeryDiclofenacMEDLINEOrthodonticsKappa indexInterferon-gammaAnimalsHumansbusiness.industryOsteoprotegerinBone physiologyIsoxazolesOrthodontic Anchorage ProceduresAcetylcysteineRatslcsh:RK1-715CelecoxibResveratrolTooth movementlcsh:DentistryClodronic Acidbusiness
researchProduct

Drug-induced expansion and differentiation of Vγ9Vδ2 T cells in vivo: The role of exogenous IL-2

2005

Human Vgamma9Vdelta2 T cells recognize nonpeptidic Ags generated by the 1-deoxy-d-xylulose 5-phosphate (many eubacteria, algae, plants, and Apicomplexa) and mevalonate (eukaryotes, archaebacteria, and certain eubacteria) pathways of isoprenoid synthesis. The potent Vgamma9Vdelta2 T cell reactivity 1) against certain cancer cells or 2) induced by infectious agents indicates that therapeutic augmentations of Vgamma9Vdelta2 T cell activities may be clinically beneficial. The functional characteristics of Vgamma9Vdelta2 T cells from Macaca fascicularis (cynomolgus monkey) are very similar to those from Homo sapiens. We have found that the i.v. administration of nitrogen-containing bisphosphonat…

Injections SubcutaneousT cellImmunologyCD4-CD8 RatioPamidronateBiologyPharmacologyInterferon-gammaInterleukin 21HemiterpenesOrganophosphorus CompoundsT-Lymphocyte SubsetsmedicineAnimalsImmunology and AllergyCytotoxic T cellIL-2 receptorAntigensAntigen-presenting cellCells CulturedCell ProliferationInterleukin 323-DiphosphoglycerateDiphosphonatesZAP70Cell DifferentiationReceptors Antigen T-Cell gamma-deltaTh1 CellsNatural killer T cellDiphosphatesMacaca fascicularismedicine.anatomical_structureInjections IntravenousImmunologyEpoxy CompoundsInterleukin-2Immunologic Memory
researchProduct

Role of pamidronate disodium in the treatment of metastatic bone disease.

1998

Aims and Background Bone metastases are a common feature of advanced neoplastic disease and are considered to be among the most frequent causes of pain and complications in oncologic patients. The main objective of the treatment of such patients is to control their symptoms and improve their quality of life. Pamidronate disodium is a second-generation bisphosphonate capable of inhibiting bone resorption (particularly osteoclast activity) without affecting bone reminerali-zation. After a brief introduction concerning the pathophysiology of bone metastases and neoplastic bone pain, we herein present data on the clinical pharmacology and toxicity of bisphosphonates in general, and pamidronate …

OncologyCancer Researchmedicine.medical_specialtyBone diseasemedicine.medical_treatmentPamidronateAntineoplastic AgentsBone Neoplasms030226 pharmacology & pharmacyBone resorption03 medical and health sciences0302 clinical medicineBreast cancerOsteoclastInternal medicinemedicineHumansBone ResorptionBone painMultiple myelomaPalliative therapyClinical Trials as TopicDiphosphonatesbusiness.industryMedicine (all)General MedicineBisphosphonatemedicine.diseaseRadiation therapyBone metastasemedicine.anatomical_structureOncology030220 oncology & carcinogenesisBone Remodelingmedicine.symptombusinessTumori
researchProduct